BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company founded in 1986 and headquartered in Durham, North Carolina. It is focused on the discovery, development and commercialization of small molecule drugs which target the human autoimmune and infectious diseases. The company’s range of products include RAPIVAB and RAPIACTA (SSIV) for the treatment of acute uncomplicated influenza and ORLADEYO for the treatment of hereditary angioedema.

BioCryst is also involved in the development of several new small molecule drugs including BCX9930, an oral factor D inhibitor currently in Phase II clinical trials for complement-mediated diseases, BCX9250, an oral activin receptor-like kinase-2 inhibitor currently in Phase I clinical trials for Fibrodysplasia Ossificans Progressiva, and Galidesivir, a RNA dependent-RNA polymerase inhibitor which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola and Zika.

The company has collaborations and in-license relationships with some of the leading pharmaceutical companies such as Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, Mundipharma International Holdings Limited, and many others. Additionally, BioCryst is engaged in collaborations and in-license arrangements with various academic and government institutions, including the National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd.

BioCryst works with a team of experienced scientists and professionals, who are dedicated to the discovery and development of novel, life-saving, small molecule medicines. The company is continuously looking for new and innovative ways to develop treatments for underserved and hard-to-treat diseases. Its focus on cutting-edge research allows it to develop treatments for conditions that were previously considered untreatable. In addition, BioCryst is committed to providing access to its medicines at an affordable cost with the ultimate goal of improving the quality of life of its patients.